ArticleFuture oncology (London, England)2021
Trastuzumab deruxtecan in previously treated HER2-positive metastatic breast cancer: Plain language summary of the DESTINY-Breast01 study.
Article in Future oncology (London, England), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 28 citations in OpenAlex.
- Precision Therapeutics in Pancreatic Cancer: Emerging Targeted, Immune, and Antibody-Drug Conjugate Strategies Exemplified by Adagrasib, Dostarlimab, and Trastuzumab Deruxtecan.Journal of clinical medicine · 2026Review
- ADC Conjugation Strategies: From Technological Evolution to a Practical Selection Framework.Pharmaceutics · 2026Review
- Clinical presentations and prognostication of HER2-low and HER2-zero early breast cancer in Taiwan.Journal of the Chinese Medical Association : JCMA · 2026Article
- Antibody-Drug Conjugates Powered by Deruxtecan: Innovations and Challenges in Oncology.International journal of molecular sciences · 2025Review
- HER-2 SMASH.Cancer chemotherapy and pharmacology · 2024Article
- Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients.The oncologist · 2024Article
- Open questions, current challenges, and future perspectives in targeting human epidermal growth factor receptor 2-low breast cancer.ESMO open · 2024Review
- Trastuzumab in patients with breast cancer and pre-existing left ventricular systolic dysfunction.Cardio-oncology (London, England) · 2024Article
- Effect of HER2 expression status on the prognosis of patients with HROncology letters · 2023Article
- Bioinformatics combined with clinical data to analyze clinical characteristics and prognosis in patients with HER2 low expression breast cancer.Gland surgery · 2023Article
- Combination of radiotherapy and targeted therapy for HER2-positive breast cancer brain metastases.European journal of medical research · 2023Review
- An Insight into Molecular Targets of Breast Cancer Brain Metastasis.International journal of molecular sciences · 2022Review
- Multifocal and pathologically-confirmed brain metastasis complete response to trastuzumab deruxtecan.CNS oncology · 2022Article
- Mesenchymal Stem Cell Derived Exosomes as Nanodrug Carrier of Doxorubicin for Targeted Osteosarcoma Therapy via SDF1-CXCR4 Axis.International journal of nanomedicine · 2022Article
- Molecular Landscape ofPathology oncology research : POR · 2022Article
- Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness.Oncoimmunology · 2022Review
Corrections and comments
- Comment on
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This is a summary of the article discussing the results of the DESTINY-Breast01 study originally published in the
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.